TB-500
Thymosin Beta-4, TB4, Tβ4
A synthetic peptide that promotes tissue repair, reduces inflammation, and enhances healing by regulating actin polymerization and cell migration.
Terminated
PHASE2
NCT00311766
A Phase 2 Study on Effect of Thymosin Beta 4 on Wound Healing in Patients With Epidermolysis Bullosa
RegeneRx Biopharmaceuticals, Inc.
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT02974907
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2
ReGenTree, LLC
INTERVENTIONAL
Updated Dec 15, 2025
Withdrawn
PHASE2
NCT01311518
A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction
RegeneRx Biopharmaceuticals, Inc.
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT04555824
A Phase 1a Study of Thymosin Beta 4 in Healthy Volunteers
Beijing Northland Biotech. Co., Ltd.
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE2
NCT00382174
Study of Thymosin Beta 4 in Patients With Pressure Ulcers
RegeneRx Biopharmaceuticals, Inc.
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE2
NCT05485818
Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.Infarction
Beijing Northland Biotech. Co., Ltd.
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT04555850
A Phase 1b Study of Thymosin Beta 4 in Healthy Volunteers
Beijing Northland Biotech. Co., Ltd.
INTERVENTIONAL
Updated Dec 15, 2025
Terminated
PHASE2
NCT00598871
A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds
ReGenTree, LLC
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE2
NCT01387347
Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution in Patients With Dry Eye
ReGenTree, LLC
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT00628758
A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma
AstraZeneca
INTERVENTIONAL
Updated Dec 15, 2025
Terminated
PHASE4
NCT01417988
Prevention of Early Mortality by Presumptive Tuberculosis (TB) Treatment
Prof JMA Lange
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE3
NCT05555589
Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2
ReGenTree, LLC
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT03937882
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3
ReGenTree, LLC
INTERVENTIONAL
Updated Dec 15, 2025
Withdrawn
PHASE1
NCT00743769
A Phase 1 Safety Study of the Intravenous Administration of Thymosin Beta in Healthy Volunteers
RegeneRx Biopharmaceuticals, Inc.
INTERVENTIONAL
Updated Dec 15, 2025
Terminated
PHASE3
NCT02600429
Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1
ReGenTree, LLC
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE2
NCT00832091
Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers
RegeneRx Biopharmaceuticals, Inc.
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE2
NCT05984134
Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction
Beijing Northland Biotech. Co., Ltd.
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE2, PHASE3
NCT02597803
Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1
ReGenTree, LLC
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE2
NCT01393132
Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye
Michigan Cornea Consultants, PC
INTERVENTIONAL
Updated Dec 15, 2025
Completed
NA
NCT04745897
Accessibility of the World Health Organization's eTB Catalogue of Recommendations
McMaster University
INTERVENTIONAL
Updated Dec 15, 2025